Quanxin Biotech Reaches Licensing Agreement for QX027N, Targeting Asthma and Atopic Dermatitis
December 24, 2025
Source: drugdu
28
On December 22, Quanxin Biotech (02509) issued an announcement stating that it has entered into a licensing and collaboration agreement with LE2025 Therapeutics AG, a subsidiary of Windward Bio Group AG, authorizing it to exclusively develop and commercialize QX027N globally (excluding Mainland China, Taiwan, Hong Kong SAR and Macau SAR).
In return, the company will be entitled to receive payments of up to $700 million, including upfront payments, equity in Windward Bio, development and commercial milestone payments, and tiered royalties based on net sales of QX027N in licensed territories.
QX027N is a long-acting anti-TSLPxIL-13 bispecific antibody independently developed by the company. It successfully initiated a Phase I clinical trial on December 12, 2025, and completed the enrollment of the first subject. This antibody is intended for the treatment of asthma and atopic dermatitis and has received implied approval for clinical trials from the Center for Drug Evaluation of the National Medical Products Administration. The company stated that shareholders and potential investors should exercise caution when trading company shares.
https://finance.eastmoney.com/a/202512223598039165.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Over $2 billion! Another major deal for a domestically developed innovative drug December 24, 2025
- Good news for middle-aged and elderly men! Taincon has become the first generic version of a compound drug for benign prostatic hyperplasia December 24, 2025
- BeiGene – Catadegbrutinib Initiates International Multicenter Phase II Clinical Trial for B-Cell Leukemia December 24, 2025
- IND for Oral Small-Molecule KRAS G12D Inhibitor ABSK141 Approved by NMPA December 24, 2025
- Wantai Bio’s bivalent HPV vaccine (Escherichia coli) was shortlisted for the National Immunization Program (NIP) December 24, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
